(MedPage Today) -- The new oral anticoagulants, or NOACs -- dabigatran (Pradaxa), rivaroxaban (Xarelto), and Eliquis (apixaban) -- are touted for their safety, efficacy, and ease of use, but they have one drawback in common: There is no antidote. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment